Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting

By sjmartinez • March 17, 2023

Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G, Cheng WW, Flahavan EM, Kota V, Greenwald DR. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting. Clin Lymphoma Myeloma Leuk. 2023 Feb 11:S2152-2650(23)00037-X. doi: 10.1016/j.clml.2023.02.002. Epub ahead of print. PMID: 36925388.

Tags: Acute myeloid leukemia, Azacitidine, Decitabine, Hematology/Oncology, Outcomes research, Publications, Real-word data

Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein[...]

Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium

Ho AS, Moyers JT, Attarian S, Banker R, Birkeland A, Chen MM, Coffey CS, Guo T, Haidar Y, Harris JP, Holsinger FC, Inman J, Jang[...]

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Béguelin W, Casulo C, Cerhan[...]